• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

NIDA IRP

National Institute on Drug Abuse - Intramural Research Program

  National Institute on Drug Abuse | NIH IRP | Treatment Info | Emergency Contacts
  • Home
  • News
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers

Lei Shi, Ph.D.

Lei Shi, Ph.D.

Position

Chief, Computational Chemistry and Molecular Biophysics Section

Contact

Triad Technology Center
333 Cassell Drive
Room 1121
Baltimore, MD 21224

Phone: 667-312-5284

Email: lei.shi2@nih.gov

Education

Post-doctoral Training - Center for Molecular Recognition, Columbia University Medical Center (advisor: Dr. Jonathan A. Javitch); Department of Physiology and Biophysics and Institute for Computational Biomedicine, Weill Cornell Medical College (advisor: Dr. Harel Weinstein)

Ph.D. - Pharmacology, Columbia University Medical Center (advisor: Dr. Jonathan A. Javitch)

B.S. - Biochemistry and Molecular Biology, Beijing University

Research Interests

Membrane proteins (MP) initiate intracellular signaling pathways, control the flow of energy and materials in and out of the cell, and thereby account for more than 30% of the human proteome and 40% of drug targets. Research interest in the lab is focused on investigating structural basis of MP functions to advance mechanistic understanding of key cellular processes. Using a combined computational and experimental approach, we identify and characterize the elements that determine the recognitions between MP and their cognate ligands, between MP and their coupled proteins, and between MP and lipid environment. The integrated findings allow us to rationally develop small-molecule compounds for novel drug discovery.

Publications


PubMed | Google Scholar

Selected Publications

Research


2022

Asher, Wesley B; Terry, Daniel S; Gregorio, G Glenn A; Kahsai, Alem W; Borgia, Alessandro; Xie, Bing; Modak, Arnab; Zhu, Ying; Jang, Wonjo; Govindaraju, Alekhya; Huang, Li-Yin; Inoue, Asuka; Lambert, Nevin A; Gurevich, Vsevolod V; Shi, Lei; Lefkowitz, Robert J; Blanchard, Scott C; Javitch, Jonathan A

GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision Journal Article

In: Cell, 2022, ISSN: 1097-4172.

Abstract | Links

@article{pmid35483373,
title = {GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision},
author = {Wesley B Asher and Daniel S Terry and G Glenn A Gregorio and Alem W Kahsai and Alessandro Borgia and Bing Xie and Arnab Modak and Ying Zhu and Wonjo Jang and Alekhya Govindaraju and Li-Yin Huang and Asuka Inoue and Nevin A Lambert and Vsevolod V Gurevich and Lei Shi and Robert J Lefkowitz and Scott C Blanchard and Jonathan A Javitch},
url = {https://pubmed.ncbi.nlm.nih.gov/35483373/},
doi = {10.1016/j.cell.2022.03.042},
issn = {1097-4172},
year = {2022},
date = {2022-04-01},
urldate = {2022-04-01},
journal = {Cell},
abstract = {β-arrestins bind G protein-coupled receptors to terminate G protein signaling and to facilitate other downstream signaling pathways. Using single-molecule fluorescence resonance energy transfer imaging, we show that β-arrestin is strongly autoinhibited in its basal state. Its engagement with a phosphopeptide mimicking phosphorylated receptor tail efficiently releases the β-arrestin tail from its N domain to assume distinct conformations. Unexpectedly, we find that β-arrestin binding to phosphorylated receptor, with a phosphorylation barcode identical to the isolated phosphopeptide, is highly inefficient and that agonist-promoted receptor activation is required for β-arrestin activation, consistent with the release of a sequestered receptor C tail. These findings, together with focused cellular investigations, reveal that agonism and receptor C-tail release are specific determinants of the rate and efficiency of β-arrestin activation by phosphorylated receptor. We infer that receptor phosphorylation patterns, in combination with receptor agonism, synergistically establish the strength and specificity with which diverse, downstream β-arrestin-mediated events are directed.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

β-arrestins bind G protein-coupled receptors to terminate G protein signaling and to facilitate other downstream signaling pathways. Using single-molecule fluorescence resonance energy transfer imaging, we show that β-arrestin is strongly autoinhibited in its basal state. Its engagement with a phosphopeptide mimicking phosphorylated receptor tail efficiently releases the β-arrestin tail from its N domain to assume distinct conformations. Unexpectedly, we find that β-arrestin binding to phosphorylated receptor, with a phosphorylation barcode identical to the isolated phosphopeptide, is highly inefficient and that agonist-promoted receptor activation is required for β-arrestin activation, consistent with the release of a sequestered receptor C tail. These findings, together with focused cellular investigations, reveal that agonism and receptor C-tail release are specific determinants of the rate and efficiency of β-arrestin activation by phosphorylated receptor. We infer that receptor phosphorylation patterns, in combination with receptor agonism, synergistically establish the strength and specificity with which diverse, downstream β-arrestin-mediated events are directed.

Close

  • https://pubmed.ncbi.nlm.nih.gov/35483373/
  • doi:10.1016/j.cell.2022.03.042

Close

2021

Lee, Kuo Hao; Fant, Andrew D; Guo, Jiqing; Guan, Andy; Jung, Joslyn; Kudaibergenova, Mary; Miranda, Williams E; Ku, Therese; Cao, Jianjing; Wacker, Soren; Duff, Henry J; Newman, Amy Hauck; Noskov, Sergei Y; Shi, Lei

Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach Journal Article

In: J Chem Inf Model, vol. 61, no. 9, pp. 4266–4279, 2021, ISSN: 1549-960X.

Abstract | Links

@article{pmid34420294,
title = {Toward Reducing hERG Affinities for DAT Inhibitors with a Combined Machine Learning and Molecular Modeling Approach},
author = {Kuo Hao Lee and Andrew D Fant and Jiqing Guo and Andy Guan and Joslyn Jung and Mary Kudaibergenova and Williams E Miranda and Therese Ku and Jianjing Cao and Soren Wacker and Henry J Duff and Amy Hauck Newman and Sergei Y Noskov and Lei Shi},
url = {https://pubmed.ncbi.nlm.nih.gov/34420294/},
doi = {10.1021/acs.jcim.1c00856},
issn = {1549-960X},
year = {2021},
date = {2021-01-01},
urldate = {2021-01-01},
journal = {J Chem Inf Model},
volume = {61},
number = {9},
pages = {4266--4279},
abstract = {Psychostimulant drugs, such as cocaine, inhibit dopamine reuptake via blockading the dopamine transporter (DAT), which is the primary mechanism underpinning their abuse. Atypical DAT inhibitors are dissimilar to cocaine and can block cocaine- or methamphetamine-induced behaviors, supporting their development as part of a treatment regimen for psychostimulant use disorders. When developing these atypical DAT inhibitors as medications, it is necessary to avoid off-target binding that can produce unwanted side effects or toxicities. In particular, the blockade of a potassium channel, human (hERG), can lead to potentially lethal ventricular tachycardia. In this study, we established a counter screening platform for DAT and against hERG binding by combining machine learning-based quantitative structure-activity relationship (QSAR) modeling, experimental validation, and molecular modeling and simulations. Our results show that the available data are adequate to establish robust QSAR models, as validated by chemical synthesis and pharmacological evaluation of a validation set of DAT inhibitors. Furthermore, the QSAR models based on subsets of the data according to experimental approaches used have predictive power as well, which opens the door to target specific functional states of a protein. Complementarily, our molecular modeling and simulations identified the structural elements responsible for a pair of DAT inhibitors having opposite binding affinity trends at DAT and hERG, which can be leveraged for rational optimization of lead atypical DAT inhibitors with desired pharmacological properties.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

Psychostimulant drugs, such as cocaine, inhibit dopamine reuptake via blockading the dopamine transporter (DAT), which is the primary mechanism underpinning their abuse. Atypical DAT inhibitors are dissimilar to cocaine and can block cocaine- or methamphetamine-induced behaviors, supporting their development as part of a treatment regimen for psychostimulant use disorders. When developing these atypical DAT inhibitors as medications, it is necessary to avoid off-target binding that can produce unwanted side effects or toxicities. In particular, the blockade of a potassium channel, human (hERG), can lead to potentially lethal ventricular tachycardia. In this study, we established a counter screening platform for DAT and against hERG binding by combining machine learning-based quantitative structure-activity relationship (QSAR) modeling, experimental validation, and molecular modeling and simulations. Our results show that the available data are adequate to establish robust QSAR models, as validated by chemical synthesis and pharmacological evaluation of a validation set of DAT inhibitors. Furthermore, the QSAR models based on subsets of the data according to experimental approaches used have predictive power as well, which opens the door to target specific functional states of a protein. Complementarily, our molecular modeling and simulations identified the structural elements responsible for a pair of DAT inhibitors having opposite binding affinity trends at DAT and hERG, which can be leveraged for rational optimization of lead atypical DAT inhibitors with desired pharmacological properties.

Close

  • https://pubmed.ncbi.nlm.nih.gov/34420294/
  • doi:10.1021/acs.jcim.1c00856

Close

2020

Plenge, Per; Abramyan, Ara M; Sørensen, Gunnar; Mørk, Arne; Weikop, Pia; Gether, Ulrik; Bang-Andersen, Benny; Shi, Lei; Loland, Claus J

The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter Journal Article

In: Nature Communications, vol. 11, no. 1, pp. 1491, 2020, ISBN: 2041-1723.

Abstract | Links

@article{Plenge:2020aab,
title = {The mechanism of a high-affinity allosteric inhibitor of the serotonin transporter},
author = {Per Plenge and Ara M Abramyan and Gunnar Sørensen and Arne Mørk and Pia Weikop and Ulrik Gether and Benny Bang-Andersen and Lei Shi and Claus J Loland},
url = {https://pubmed.ncbi.nlm.nih.gov/32198394/},
doi = {10.1038/s41467-020-15292-y},
isbn = {2041-1723},
year = {2020},
date = {2020-01-01},
journal = {Nature Communications},
volume = {11},
number = {1},
pages = {1491},
abstract = {The serotonin transporter (SERT) terminates serotonin signaling by rapid presynaptic reuptake. SERT activity is modulated by antidepressants, e.g., S-citalopram and imipramine, to alleviate symptoms of depression and anxiety. SERT crystal structures reveal two S-citalopram binding pockets in the central binding (S1) site and the extracellular vestibule (S2 site). In this study, our combined in vitro and in silico analysis indicates that the bound S-citalopram or imipramine in S1 is allosterically coupled to the ligand binding to S2 through altering protein conformations. Remarkably, SERT inhibitor Lu AF60097, the first high-affinity S2-ligand reported and characterized here, allosterically couples the ligand binding to S1 through a similar mechanism. The SERT inhibition by Lu AF60097 is demonstrated by the potentiated imipramine binding and increased hippocampal serotonin level in rats. Together, we reveal a S1-S2 coupling mechanism that will facilitate rational design of high-affinity SERT allosteric inhibitors.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

The serotonin transporter (SERT) terminates serotonin signaling by rapid presynaptic reuptake. SERT activity is modulated by antidepressants, e.g., S-citalopram and imipramine, to alleviate symptoms of depression and anxiety. SERT crystal structures reveal two S-citalopram binding pockets in the central binding (S1) site and the extracellular vestibule (S2 site). In this study, our combined in vitro and in silico analysis indicates that the bound S-citalopram or imipramine in S1 is allosterically coupled to the ligand binding to S2 through altering protein conformations. Remarkably, SERT inhibitor Lu AF60097, the first high-affinity S2-ligand reported and characterized here, allosterically couples the ligand binding to S1 through a similar mechanism. The SERT inhibition by Lu AF60097 is demonstrated by the potentiated imipramine binding and increased hippocampal serotonin level in rats. Together, we reveal a S1-S2 coupling mechanism that will facilitate rational design of high-affinity SERT allosteric inhibitors.

Close

  • https://pubmed.ncbi.nlm.nih.gov/32198394/
  • doi:10.1038/s41467-020-15292-y

Close

Lane, Robert J; Abramyan, Ara M; Adhikari, Pramisha; Keen, Alastair C; Lee, Kuo-Hao; Sanchez, Julie; Verma, Ravi Kumar; Lim, Herman D; Yano, Hideaki; Javitch, Jonathan A; Shi, Lei

Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism Journal Article

In: eLife, vol. 9, pp. e52189, 2020, ISSN: 2050-084X.

Abstract | Links

@article{10.7554/eLife.52189,
title = {Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism},
author = {Robert J Lane and Ara M Abramyan and Pramisha Adhikari and Alastair C Keen and Kuo-Hao Lee and Julie Sanchez and Ravi Kumar Verma and Herman D Lim and Hideaki Yano and Jonathan A Javitch and Lei Shi},
editor = {Yibing Shan and Richard W Aldrich},
url = {https://pubmed.ncbi.nlm.nih.gov/31985399/},
doi = {10.7554/eLife.52189},
issn = {2050-084X},
year = {2020},
date = {2020-01-01},
journal = {eLife},
volume = {9},
pages = {e52189},
publisher = {eLife Sciences Publications, Ltd},
abstract = {By analyzing and simulating inactive conformations of the highly homologous dopamine Dtextsubscript2 and Dtextsubscript3 receptors (Dtextsubscript2R and Dtextsubscript3R), we find that eticlopride binds Dtextsubscript2R in a pose very similar to that in the Dtextsubscript3R/eticlopride structure but incompatible with the Dtextsubscript2R/risperidone structure. In addition, risperidone occupies a sub-pocket near the Natextsuperscript+ binding site, whereas eticlopride does not. Based on these findings and our experimental results, we propose that the divergent receptor conformations stabilized by Natextsuperscript+-sensitive eticlopride and Natextsuperscript+-insensitive risperidone correspond to different degrees of inverse agonism. Moreover, our simulations reveal that the extracellular loops are highly dynamic, with spontaneous transitions of extracellular loop 2 from the helical conformation in the Dtextsubscript2R/risperidone structure to an extended conformation similar to that in the Dtextsubscript3R/eticlopride structure. Our results reveal previously unappreciated diversity and dynamics in the inactive conformations of Dtextsubscript2R. These findings are critical for rational drug discovery, as limiting a virtual screen to a single conformation will miss relevant ligands.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

By analyzing and simulating inactive conformations of the highly homologous dopamine Dtextsubscript2 and Dtextsubscript3 receptors (Dtextsubscript2R and Dtextsubscript3R), we find that eticlopride binds Dtextsubscript2R in a pose very similar to that in the Dtextsubscript3R/eticlopride structure but incompatible with the Dtextsubscript2R/risperidone structure. In addition, risperidone occupies a sub-pocket near the Natextsuperscript+ binding site, whereas eticlopride does not. Based on these findings and our experimental results, we propose that the divergent receptor conformations stabilized by Natextsuperscript+-sensitive eticlopride and Natextsuperscript+-insensitive risperidone correspond to different degrees of inverse agonism. Moreover, our simulations reveal that the extracellular loops are highly dynamic, with spontaneous transitions of extracellular loop 2 from the helical conformation in the Dtextsubscript2R/risperidone structure to an extended conformation similar to that in the Dtextsubscript3R/eticlopride structure. Our results reveal previously unappreciated diversity and dynamics in the inactive conformations of Dtextsubscript2R. These findings are critical for rational drug discovery, as limiting a virtual screen to a single conformation will miss relevant ligands.

Close

  • https://pubmed.ncbi.nlm.nih.gov/31985399/
  • doi:10.7554/eLife.52189

Close

2019

Abramyan, Ara M; Slack, Rachel D; Meena, Sitaram; Davis, Bruce A; Newman, Amy Hauck; Singh, Satinder K; Shi, Lei

Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics Journal Article

In: Neuropharmacology, vol. 161, pp. 107411, 2019, ISSN: 0028-3908, (Neurotransmitter Transporters).

Abstract | Links

@article{ABRAMYAN2019107411,
title = {Computation-guided analysis of paroxetine binding to hSERT reveals functionally important structural elements and dynamics},
author = {Ara M Abramyan and Rachel D Slack and Sitaram Meena and Bruce A Davis and Amy Hauck Newman and Satinder K Singh and Lei Shi},
url = {https://pubmed.ncbi.nlm.nih.gov/30391505/},
doi = {https://doi.org/10.1016/j.neuropharm.2018.10.040},
issn = {0028-3908},
year = {2019},
date = {2019-01-01},
journal = {Neuropharmacology},
volume = {161},
pages = {107411},
abstract = {The serotonin transporter (SERT) is one of the primary targets for medications to treat neuropsychiatric disorders and functions by exploiting pre-existing ion gradients of Na+, Cl−, and K+ to translocate serotonin from the synaptic cleft into the presynaptic neuron. Although recent hSERT crystal structures represent a milestone for structure-function analyses of mammalian neurotransmitter:sodium symporters, they are all derived from thermostabilized but transport-deficient constructs. Two of these structures are in complex with paroxetine, the most potent selective serotonin reuptake inhibitor known. In this study, by carrying out and analyzing the results of extensive and comparative molecular dynamics simulations while also re-evaluating the transport and binding properties of the thermostabilized constructs, we identified functionally important structural elements that are perturbed by these mutations, revealed unexpected dynamics in the central primary binding site of SERT, and uncovered a conceivable ambiguity in paroxetine's binding orientation. We propose that the favored entropy contribution plays a significant role in paroxetine's extraordinarily high affinity for SERT. Our findings lay the foundation for future mechanistic studies and rational design of high-affinity SERT inhibitors. This article is part of the issue entitled `Special Issue on Neurotransmitter Transporters'.},
note = {Neurotransmitter Transporters},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

The serotonin transporter (SERT) is one of the primary targets for medications to treat neuropsychiatric disorders and functions by exploiting pre-existing ion gradients of Na+, Cl−, and K+ to translocate serotonin from the synaptic cleft into the presynaptic neuron. Although recent hSERT crystal structures represent a milestone for structure-function analyses of mammalian neurotransmitter:sodium symporters, they are all derived from thermostabilized but transport-deficient constructs. Two of these structures are in complex with paroxetine, the most potent selective serotonin reuptake inhibitor known. In this study, by carrying out and analyzing the results of extensive and comparative molecular dynamics simulations while also re-evaluating the transport and binding properties of the thermostabilized constructs, we identified functionally important structural elements that are perturbed by these mutations, revealed unexpected dynamics in the central primary binding site of SERT, and uncovered a conceivable ambiguity in paroxetine's binding orientation. We propose that the favored entropy contribution plays a significant role in paroxetine's extraordinarily high affinity for SERT. Our findings lay the foundation for future mechanistic studies and rational design of high-affinity SERT inhibitors. This article is part of the issue entitled `Special Issue on Neurotransmitter Transporters'.

Close

  • https://pubmed.ncbi.nlm.nih.gov/30391505/
  • doi:https://doi.org/10.1016/j.neuropharm.2018.10.040

Close

2018

Verma, R K; Abramyan, A M; Michino, M; Free, R B; Sibley, D R; Javitch, J A; Lane, J R; Shi, L

The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors Journal Article

In: PLoS Comput Biol, vol. 14, no. 1, pp. e1005948, 2018, ISSN: 1553-7358 (Electronic) 1553-734X (Linking).

Links

@article{RN9711,
title = {The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors},
author = {R K Verma and A M Abramyan and M Michino and R B Free and D R Sibley and J A Javitch and J R Lane and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/29337986},
doi = {10.1371/journal.pcbi.1005948},
issn = {1553-7358 (Electronic) 1553-734X (Linking)},
year = {2018},
date = {2018-01-01},
journal = {PLoS Comput Biol},
volume = {14},
number = {1},
pages = {e1005948},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/29337986
  • doi:10.1371/journal.pcbi.1005948

Close

Yano, H; Bonifazi, A; Xu, M; Guthrie, D A; Schneck, S N; Abramyan, A M; Fant, A D; Hong, W C; Newman, Amy Hauck; Shi, L

Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays Journal Article

In: Neuropharmacology, vol. 133, pp. 264-275, 2018, ISSN: 1873-7064 (Electronic) 0028-3908 (Linking).

Links

@article{RN9724,
title = {Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays},
author = {H Yano and A Bonifazi and M Xu and D A Guthrie and S N Schneck and A M Abramyan and A D Fant and W C Hong and Amy Hauck Newman and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/29407216},
doi = {10.1016/j.neuropharm.2018.01.042},
issn = {1873-7064 (Electronic) 0028-3908 (Linking)},
year = {2018},
date = {2018-01-01},
urldate = {2018-01-01},
journal = {Neuropharmacology},
volume = {133},
pages = {264-275},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/29407216
  • doi:10.1016/j.neuropharm.2018.01.042

Close

2017

Abramyan, A M; Stolzenberg, S; Li, Z; Loland, C J; Noe, F; Shi, L

The Isomeric Preference of an Atypical Dopamine Transporter Inhibitor Contributes to Its Selection of the Transporter Conformation Journal Article

In: ACS Chem Neurosci, vol. 8, no. 8, pp. 1735-1746, 2017, ISSN: 1948-7193 (Electronic) 1948-7193 (Linking).

Links

@article{RN9683,
title = {The Isomeric Preference of an Atypical Dopamine Transporter Inhibitor Contributes to Its Selection of the Transporter Conformation},
author = {A M Abramyan and S Stolzenberg and Z Li and C J Loland and F Noe and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28441487},
doi = {10.1021/acschemneuro.7b00094},
issn = {1948-7193 (Electronic) 1948-7193 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {ACS Chem Neurosci},
volume = {8},
number = {8},
pages = {1735-1746},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/28441487
  • doi:10.1021/acschemneuro.7b00094

Close

Michino, M; Boateng, C A; Donthamsetti, P; Yano, H; Bakare, O M; Bonifazi, A; Ellenberger, M P; Keck, T M; Kumar, V; Zhu, C; Verma, R; Deschamps, J R; Javitch, J A; Newman, Amy Hauck; Shi, L

Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor Journal Article

In: J Med Chem, vol. 60, no. 2, pp. 580-593, 2017, ISSN: 1520-4804 (Electronic) 0022-2623 (Linking).

Links

@article{RN9670,
title = {Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor},
author = {M Michino and C A Boateng and P Donthamsetti and H Yano and O M Bakare and A Bonifazi and M P Ellenberger and T M Keck and V Kumar and C Zhu and R Verma and J R Deschamps and J A Javitch and Amy Hauck Newman and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27983845},
doi = {10.1021/acs.jmedchem.6b01148},
issn = {1520-4804 (Electronic) 0022-2623 (Linking)},
year = {2017},
date = {2017-01-01},
urldate = {2017-01-01},
journal = {J Med Chem},
volume = {60},
number = {2},
pages = {580-593},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/27983845
  • doi:10.1021/acs.jmedchem.6b01148

Close

Stolzenberg, S; Li, Z; Quick, M; Malinauskaite, L; Nissen, P; Weinstein, H; Javitch, J A; Shi, L

The role of transmembrane segment 5 (TM5) in Na2 release and the conformational transition of neurotransmitter:sodium symporters toward the inward-open state Journal Article

In: J Biol Chem, vol. 292, no. 18, pp. 7372-7384, 2017, ISSN: 1083-351X (Electronic) 0021-9258 (Linking).

Links

@article{RN9684,
title = {The role of transmembrane segment 5 (TM5) in Na2 release and the conformational transition of neurotransmitter:sodium symporters toward the inward-open state},
author = {S Stolzenberg and Z Li and M Quick and L Malinauskaite and P Nissen and H Weinstein and J A Javitch and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28320858},
doi = {10.1074/jbc.M116.757153},
issn = {1083-351X (Electronic) 0021-9258 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {J Biol Chem},
volume = {292},
number = {18},
pages = {7372-7384},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/28320858
  • doi:10.1074/jbc.M116.757153

Close

2016

Stolzenberg, S; Michino, M; LeVine, M V; Weinstein, H; Shi, L

Computational approaches to detect allosteric pathways in transmembrane molecular machines Journal Article

In: Biochim Biophys Acta, vol. 1858, no. 7 Pt B, pp. 1652-62, 2016, ISSN: 0006-3002 (Print) 0006-3002 (Linking).

Links

@article{RN8556,
title = {Computational approaches to detect allosteric pathways in transmembrane molecular machines},
author = {S Stolzenberg and M Michino and M V LeVine and H Weinstein and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/26806157},
doi = {10.1016/j.bbamem.2016.01.010},
issn = {0006-3002 (Print) 0006-3002 (Linking)},
year = {2016},
date = {2016-01-01},
journal = {Biochim Biophys Acta},
volume = {1858},
number = {7 Pt B},
pages = {1652-62},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/26806157
  • doi:10.1016/j.bbamem.2016.01.010

Close

Review


2018

Sibley, D R; Shi, L

A new era of rationally designed antipsychotics Journal Article

In: Nature, vol. 555, no. 7695, pp. 170-172, 2018, ISSN: 1476-4687 (Electronic) 0028-0836 (Linking).

Links

@article{RN9885,
title = {A new era of rationally designed antipsychotics},
author = {D R Sibley and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/29517027},
doi = {10.1038/d41586-018-02328-z},
issn = {1476-4687 (Electronic) 0028-0836 (Linking)},
year = {2018},
date = {2018-01-01},
journal = {Nature},
volume = {555},
number = {7695},
pages = {170-172},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/29517027
  • doi:10.1038/d41586-018-02328-z

Close

2017

Beuming, T; Shi, L

Editorial: Computer Aided Structure-based Lead Optimization Journal Article

In: Curr Top Med Chem, vol. 17, no. 23, pp. 2575-2576, 2017, ISSN: 1873-4294 (Electronic) 1568-0266 (Linking).

Links

@article{RN9713,
title = {Editorial: Computer Aided Structure-based Lead Optimization},
author = {T Beuming and L Shi},
url = {https://www.ncbi.nlm.nih.gov/pubmed/28889794},
doi = {10.2174/156802661723170808161306},
issn = {1873-4294 (Electronic) 1568-0266 (Linking)},
year = {2017},
date = {2017-01-01},
journal = {Curr Top Med Chem},
volume = {17},
number = {23},
pages = {2575-2576},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/28889794
  • doi:10.2174/156802661723170808161306

Close

2015

Michino, M.; Beuming, T.; Donthamsetti, P.; Newman, Amy Hauck; Javitch, J. A.; Shi, L.

What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands? Journal Article

In: Pharmacol Rev, vol. 67, no. 1, pp. 198–213, 2015, ISSN: 1521-0081 (Electronic); 0031-6997 (Linking).

Abstract | Links

@article{Michino2015b,
title = {What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?},
author = {Michino, M. and Beuming, T. and Donthamsetti, P. and Amy Hauck Newman and Javitch, J. A. and Shi, L.},
url = {https://www.ncbi.nlm.nih.gov/pubmed/25527701},
doi = {10.1124/pr.114.009944},
issn = {1521-0081 (Electronic); 0031-6997 (Linking)},
year = {2015},
date = {2015-12-20},
urldate = {2015-12-20},
journal = {Pharmacol Rev},
volume = {67},
number = {1},
pages = {198--213},
abstract = {G protein-coupled receptors (GPCRs) are integral membrane proteins that represent an important class of drug targets. In particular, aminergic GPCRs interact with a significant portion of drugs currently on the market. However, most drugs that target these receptors are associated with undesirable side effects, which are due in part to promiscuous interactions with close homologs of the intended target receptors. Here, based on a systematic analysis of all 37 of the currently available high-resolution crystal structures of aminergic GPCRs, we review structural elements that contribute to and can be exploited for designing subtype-selective compounds. We describe the roles of secondary binding pockets (SBPs), as well as differences in ligand entry pathways to the orthosteric binding site, in determining selectivity. In addition, using the available crystal structures, we have identified conformational changes in the SBPs that are associated with receptor activation and explore the implications of these changes for the rational development of selective ligands with tailored efficacy.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}

Close

G protein-coupled receptors (GPCRs) are integral membrane proteins that represent an important class of drug targets. In particular, aminergic GPCRs interact with a significant portion of drugs currently on the market. However, most drugs that target these receptors are associated with undesirable side effects, which are due in part to promiscuous interactions with close homologs of the intended target receptors. Here, based on a systematic analysis of all 37 of the currently available high-resolution crystal structures of aminergic GPCRs, we review structural elements that contribute to and can be exploited for designing subtype-selective compounds. We describe the roles of secondary binding pockets (SBPs), as well as differences in ligand entry pathways to the orthosteric binding site, in determining selectivity. In addition, using the available crystal structures, we have identified conformational changes in the SBPs that are associated with receptor activation and explore the implications of these changes for the rational development of selective ligands with tailored efficacy.

Close

  • https://www.ncbi.nlm.nih.gov/pubmed/25527701
  • doi:10.1124/pr.114.009944

Close

Primary Sidebar

Organization

  • Organization
  • Faculty
  • Office of the Scientific Director
  • Office of the Clinical Director
  • Administrative Management Branch
  • Molecular Targets and Medications Discovery Branch
  • Cellular and Neurocomputational Systems Branch
  • Molecular Neuropsychiatry Research Branch
  • Neuroimaging Research Branch
  • Behavioral Neuroscience Research Branch
  • Integrative Neuroscience Research Branch
  • Translational Addiction Medicine Branch
  • Core Facilities
  • Careers at NIDA IRP
  • Technology Development Initiative
  • Community Outreach Group
Home / Staff Members / Lei Shi, Ph.D.
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links
  • National Institute on Drug Abuse
  • NIH Intramural Research Program
  • National Institutes of Health
  • Health and Human Services
  • USA.GOV
  • Emergency Contacts
  • Employee Assistance
  • Treatment Information
  • Contact Us
  • Careers at NIDA IRP
  • Accessibility
  • Privacy
  • HHS Vulnerability Disclosure
  • Freedom of Information Act
  • Document Viewing Tools
  • Offsite Links

  • Home
  • News
    ▼
    • Featured Paper of the Month
    • Reviews to Read
    • Hot off the Press
    • IRP News
    • Awards
    • Technology Development Initiative Paper of the Month
    • Seminar Series
    • Addiction Grand Rounds
  • About
    ▼
    • About NIDA IRP
    • Contact Us
    • Directions and Map
    • Careers at NIDA IRP
    • Emergency Contacts
    • Employee Assistance Resources
  • Organization
    ▼
    • Faculty
    • Office of the Scientific Director
    • Office of the Clinical Director
    • Office of Education and Career Development
    • Administrative Management Branch
    • Molecular Targets and Medications Discovery Branch
    • Cellular and Neurocomputational Systems Branch
    • Molecular Neuropsychiatry Research Branch
    • Neuroimaging Research Branch
    • Behavioral Neuroscience Research Branch
    • Integrative Neuroscience Research Branch
    • Translational Addiction Medicine Branch
    • Core Facilities
    • Community Outreach Group
  • Training Programs
    ▼
    • Office of Education and Career Development
    • OECD Awards
    • Summer Internship Program
    • Postbaccalaureate Program
    • Graduate Partnership Program
    • Postdoctoral Program
    • NIDA Speakers Bureau
    • Clinical Electives Program
    • Clinical Mentoring Program
  • Study Volunteers